Abstract Details

Title Prognostic Factors and Survival in Primary CNS Lymphoma Patients at Yale

Topic Neuro-oncology

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 7-013

Objective The primary objective is to describe the overall survival of primary CNS lymphoma (PCNSL) patients at Yale. Secondary objectives include determining prognostic factors and estimating event-free survival.

Background While PCNSL comprises less than 5 percent of primary brain tumors, incidence is rising in the elderly and immunocompromised populations. Curative therapy is available, but optimal treatment regimens are currently debated. These results were initially presented to the International PCNSL Collaborative Group.

Design/Methods We retrospectively analyzed patients with PCNSL treated by Yale between the years of 2000 and 2018. Kaplan-Meier survival curves were used to estimate survival outcomes. Considering sociodemographic and clinical descriptors, Cox proportional hazards regression models were used to evaluate risk factors and treatments associated with survival.

Results One hundred nineteen subjects were analyzed. This cohort has a median age of 63 years, and subjects are predominantly male (60.7%) and non-Hispanic white (80.2%). Sixty-eight patients died, and eighty-two experienced an event (disease progression or death). The median follow-up time of surviving patients is 4.09 years, and the estimated median overall survival is 3.09 years (95% CI: 1.80 years to 5.98 years). Age and first-line therapy significantly impacted overall survival. Patients younger than 50 and those of age 50 or older had median overall survival estimates of 8.20 and 2.63 years, respectively. Patients treated without Methotrexate had a median overall survival of 1.05 years, much lower than that of patients whose treatment included Methotrexate, with a median overall survival of 5.46 years. The estimated median event-free survival is 1.32 years (95% CI: 0.88 years to 2.15 years).

Conclusions We describe a large cohort of PCNSL patients treated at a single institution with median overall and progression-free survival estimates comparable to similar studies. Multi-institutional investigations may further clarify the prognostic roles of risk factors and treatment regimens for improved PCNSL patient survival.

Authors/Disclosures
Isabel Prado (Yale University School of Medicine) PRESENTER	No disclosure on file
	No disclosure on file
Joachim M. Baehring, MD, FAAN (Yale University School of Medicine)	Dr. Baehring has nothing to disclose.
Kevin P. Becker, MD, PhD	No disclosure on file
Zachary A. Corbin, MD, MHS (Boehringer Ingelheim Pharmaceuticals, Inc.)	No disclosure on file

��ɫ��

��ɫ��